bims-glumda Biomed News
on CGM data in management of diabetes
Issue of 2026–05–10
sixteen papers selected by
Mott Given



  1. Diabetes Obes Metab. 2026 May 06.
      
    Keywords:  attitudes; clinical trial; continuous glucose monitoring (CGM); dietary intervention; type 2 diabetes
    DOI:  https://doi.org/10.1111/dom.70815
  2. J Diabetes Sci Technol. 2026 May 08. 19322968261441312
       BACKGROUND: Hemoglobin A1C (HbA1C) is the gold standard for assessing long-term glycemic control in people with diabetes. Increasing use of continuous glucose monitoring (CGM) has led to adoption of the glucose management indicator (GMI) as a CGM‑based HbA1C estimate, but GMI often differs from laboratory HbA1C, especially in type 2 diabetes. This discordance may be associated with the fact that GMI, as a measure of central tendency, fails to capture temporal glycemic trends and variability that relate to HbA1C formation.
    OBJECTIVE: To evaluate whether combining CGM-derived metrics capturing variability, excursions, and temporal trends improves estimation of laboratory-measured HbA1C in type 2 diabetes.
    METHODS: A machine learning framework was applied to CGM data from a three-month randomized trial, including 159 participants with type 2 diabetes. Participants had ≥70% CGM data coverage and valid end-of-trial HbA1C. From a standardized 90-day CGM window, 51 metrics were extracted. Benchmark models (mean glucose and GMI) were compared with models developed using forward and exhaustive feature selection with threefold cross-validated multiple linear regression.
    RESULTS: Benchmark models yielded R-squared = 0.53. A forward selection model including five metrics (GMI at night, night-to-overall mean glucose ratio, glycemic risk assessment diabetes equation, time in tight range [3.0-7.8 mmol/L], time above range [13.9 mmol/L] at night) improved R-squared to 0.60. The best-performing model (substituting GRADE at night for GMI at night) achieved a similar R-squared (0.61). Nighttime and hyperglycemia‑related metrics were consistently selected.
    CONCLUSION: Continuous glucose monitoring‑based HbA1C estimation improves when variability and temporal patterns are included. Nighttime hyperglycemia adds notable predictive value, though further validation is needed.
    Keywords:  CGM metrics; HbA1C estimation; continuous glucose monitoring; glucose management indicator; machine learning; trend-based glucose modeling; type 2 diabetes
    DOI:  https://doi.org/10.1177/19322968261441312
  3. J Diabetes Sci Technol. 2026 May 08. 19322968261444045
       BACKGROUND: The number of adults with diabetes and older age is increasing, yet little is known about age-related differences in real-world diabetes technology use. This analysis examines how uptake, clinical outcomes, and user experience vary across age groups in people with type 1 or type 2 diabetes.
    METHODS: Self-reported data from 2056 individuals with diabetes in Germany, Austria, and Switzerland who completed the diabetes technology report 2024/2025 survey were analyzed. Age-related trends in the use of continuous glucose monitoring (CGM), continuous subcutaneous insulin infusion (CSII), and automated insulin delivery (AID) were assessed using generalized additive and segmented logistic regression models. Outcomes included HbA1c, diabetes distress (PAID-5), severe hypoglycemia (SH), and, among AID users, satisfaction.
    RESULTS: Among people with type 1 diabetes, CGM usage was consistently high across age groups (eg, 94% in 20-29 years; 92% in ≥70 years). Automated insulin delivery usage peaked in adolescents (81% in 10-19 years) and declined to 36% in adults ≥70 years. In type 2 diabetes, CGM use increased with age (48% in 35-44 years; 72% in ≥70 years). The HbA1c remained stable over the age span (±0.25%). Diabetes distress declined with age (Problems Areas in Diabetes Ouestionnaire - 5 Items (PAID-5): 7.8 in <30 vs 4.2 in ≥70 years). The risk of SH did not increase with age; among CSII users, older participants had lower odds of SH (OR 0.03, p = .001). Automated insulin delivery satisfaction was highest in adults aged 60 to 69 years (88.7/100) and lowest in adolescents (79.1/100).
    CONCLUSIONS: Diabetes technologies are widely used and well tolerated across age groups. Older adults benefit comparably, but barriers to AID use remain.
    Keywords:  age-related differences; automated insulin delivery; clinical outcome; continuous glucose monitoring; diabetes technology; patient-reported outcomes
    DOI:  https://doi.org/10.1177/19322968261444045
  4. Diabetes Care. 2026 May 04. pii: dc252820. [Epub ahead of print]
       OBJECTIVE: Discordance between the glucose management indicator (GMI) and hemoglobin A1c (HbA1c) is frequently observed in diabetes, yet its physiological basis remains unclear. This study investigated how specific glucose excursion patterns captured by continuous glucose monitoring (CGM) contribute to this discordance in individuals with type 1 diabetes.
    RESEARCH DESIGN AND METHODS: Ninety-day CGM traces from 611 adults with type 1 diabetes were paired with HbA1c results obtained within ±15 days. Glucose excursions were quantified using the glucose rate increase detector (GRID) algorithm with varied peak glucose and time-to-peak thresholds. Discordance was defined using GMI-to-HbA1c and updated GMI (uGMI)-to-HbA1c ratios, and associations with GRID-derived excursion metrics were evaluated alongside conventional CGM-derived variability metrics.
    RESULTS: Excursions with peak glucose ≥250 mg/dL and time to peak ≥90 min were significantly associated with higher uGMI-to-HbA1c ratios after adjustment for age, sex, eGFR, and HbA1c group, with consistent findings across CGM devices (sensor type 1: β = 0.174, 95% CI 0.147-0.201; sensor type 2: β = 0.102, 95% CI 0.068-0.136; both P < 0.001) and alternative GMI formulations. In restricted cubic spline analyses, adjustment for GRID-derived excursion metrics differentially reshaped the associations of HbA1c, GMI, and uGMI with albuminuria and elevated triglyceride-glucose (TyG) index in an outcome- and context-dependent manner, preferentially enhancing the informativeness of GMI and uGMI-but not HbA1c.
    CONCLUSIONS: Frequent high and prolonged glucose excursions were consistently associated with GMI-HbA1c discordance across devices, HbA1c strata, and analytic conditions. GRID-derived excursion metrics modify the relationship between GMI/uGMI and glycemia-associated risk.
    DOI:  https://doi.org/10.2337/dc25-2820
  5. Sensors (Basel). 2026 Apr 21. pii: 2552. [Epub ahead of print]26(8):
      Ramadan fasting substantially alters meal timing, sleep patterns, and daily activity, thereby increasing the risk of hypoglycaemia in adults with type 1 diabetes (T1D). Although continuous glucose monitoring (CGM) systems provide real-time alerts, these are largely reactive or limited to short prediction horizons, offering insufficient warning under fasting-related behavioural and circadian disruption. This study aims to evaluate whether behaviour-aware, temporally enriched recurrent deep learning models, leveraging multimodal CGM and wearable-derived signals, can forecast hypoglycaemia one hour ahead during Ramadan and the post-fasting period. In an observational, free-living cohort study conducted in Qatar, 33 adults with T1D were monitored using CGM and a wrist-worn wearable during Ramadan 2023 and the subsequent month. Multimodal data were aggregated into hourly features and organised into rolling 36 h sequences. In addition to physiological signals, explicit temporal and circadian proxy features were engineered, including cyclic time encodings, day-night indicators, and Ramadan-specific behavioural windows (e.g., pre-iftar, iftar, post-iftar, and fasting phases). Recurrent models, including LSTM and BiLSTM architectures, were trained using patient-wise, leak-free splits, with focal loss applied to address class imbalance. Model performance was evaluated on a held-out, naturally imbalanced test set using ROC AUC, precision-recall AUC, recall, and probability calibration, alongside cross-phase evaluation between Ramadan and post-fasting periods. Following quality control, 1164 participant-days were retained, with hypoglycaemia accounting for approximately 4% of hourly observations. Temporal feature enrichment and the use of a 36 h lookback window improved both discrimination and calibration, with performance stabilizing beyond this horizon. On the imbalanced test set, the best-performing multimodal model achieved an ROC AUC of 0.867 and a precision-recall AUC of 0.341, identifying 77% of next-hour hypoglycaemic events at a sensitivity-focused operating point (precision = 0.14). The selected BiLSTM model demonstrated good probability calibration (Brier score ≈ 0.03). Models trained using wearable-derived inputs alone achieved comparable discrimination and, in some configurations, higher precision-recall AUC than CGM-only baselines. Notably, models trained on the original imbalanced data outperformed resampled variants, suggesting that temporal and behavioural features provided sufficient discriminatory signal without requiring aggressive class balancing. Cross-phase evaluation indicated robust generalisation, particularly for the BiLSTM model. Overall, behaviour-aware, temporally enriched multimodal models can provide calibrated, hour-ahead hypoglycaemia risk estimates during Ramadan fasting in adults with T1D, enabling proactive intervention beyond reactive CGM alerts. Explicit modelling of circadian and behavioural dynamics enhances predictive performance under real-world class imbalance. Furthermore, integrating wearable-derived behavioural and physiological signals adds predictive value beyond CGM alone, supporting robustness across varying levels of contextual data availability. External validation and prospective clinical evaluation are required prior to deployment.
    Keywords:  Ramadan fasting; class imbalance; continuous glucose monitoring; dataset shift; deep learning; hypoglycaemia forecasting; long short-term memory; probability calibration; type 1 diabetes; wearable sensors
    DOI:  https://doi.org/10.3390/s26082552
  6. J Diabetes Sci Technol. 2026 May 06. 19322968261444041
       BACKGROUND: Diabetes technologies, such as continuous glucose monitoring (CGM), insulin pumps, and automated insulin delivery (AID) systems, are increasingly used by people with type 2 diabetes (PWT2D), with growing clinical evidence supporting their therapeutic benefit. To describe the extent of adoption, perceived benefits, and future expectations, both health care professionals (HCPs) and PWT2D data from the dt-report 2025 were analyzed.
    METHODS: From November to December 2025, HCP and PWT2D participated in the dt-report providing their attitudes, expectations, and predictions regarding the use of diabetes technology in type 2 diabetes. Frequencies from specific responses were analyzed.
    RESULTS: Data from 1078 HCPs and 450 PWT2D from the DACH region were analyzed for questions regarding the use of technology in type 2 diabetes. Continuous glucose monitoring was the most widely endorsed technology across both groups, with 58% of the survey participants using a CGM, and 1% using a pump. Health care professionals estimated 87% of PWT2D on intensive insulin therapy would benefit from CGM and saw indications among non-intensive insulin users (62%) and those on oral therapies (55%). Future use of CGM and AID systems was anticipated by both HCPs and PWT2D, including many currently not using such systems. Smart pens and stand-alone insulin pumps were viewed less favorably. Reported barriers included lack of awareness, reimbursement limitations, digital literacy, and usability concerns.
    CONCLUSION: The findings indicate growing openness toward diabetes technologies among PWT2D and broader perceived indications among HCPs. However, uptake remains limited, particularly outside of intensive insulin therapy. These insights are of relevance for future clinical guidance, access strategies, and patient education.
    Keywords:  dt-report; survey; technology; type 2 diabetes
    DOI:  https://doi.org/10.1177/19322968261444041
  7. Healthcare (Basel). 2026 Apr 13. pii: 1019. [Epub ahead of print]14(8):
      Background/Objectives: Continuous glucose monitoring (CGM) has transformed diabetes management by enabling high-resolution assessment of glucose dynamics, with well-established use in type 1 diabetes (T1D) and insulin-treated type 2 diabetes (T2D), and expanding applications across broader populations, including non-insulin-treated T2D and gestational diabetes. However, real-world implementation remains constrained by economic barriers, fragmented reimbursement, workflow challenges, and limited capacity for continuous data interpretation. This review examines key barriers to CGM implementation and synthesizes current evidence on pharmacist-integrated CGM care as an emerging model to support CGM adoption across clinical and community-based settings. Methods: A narrative literature review was conducted to synthesize evidence on pharmacist-integrated CGM services in diabetes care. Literature was identified through structured searches of PubMed, Embase, and the Cochrane Library, supplemented by Google Scholar and citation tracking, covering publications from January 2010 to December 2025. Studies were selected based on predefined criteria, including those reporting clinical outcomes, pharmacist involvement, or health system and implementation factors related to CGM use. Relevant survey-based and real-world studies were also considered to capture healthcare professionals' perspectives and implementation experiences. Evidence was synthesized thematically across clinical, behavioral, and health system domains. Results: Available evidence suggests that pharmacist-integrated CGM care is associated with improvements in glycemic management, including increased time in range, reduced glycemic variability, and more timely pharmacotherapy optimization. Pharmacist involvement may also support patient education, self-management, and engagement with digital health technologies, and facilitate ongoing data interpretation and treatment adjustment between clinical encounters. However, evidence remains heterogeneous and geographically limited, with predominantly retrospective and pilot studies and few randomized trials, constraining the robustness and external validity of the findings. Further studies are needed to confirm its clinical effectiveness, comparative effectiveness, and economic value. Conclusions: Pharmacist-integrated CGM represents a promising and operationally feasible approach to supporting CGM use in routine diabetes care. While current evidence indicates potential benefits in glycemic management and care delivery processes, further research and implementation efforts are required to support its effective and sustainable adoption across diverse healthcare settings.
    Keywords:  continuous glucose monitoring; diabetes management; digital health; medication adherence; pharmacists; therapy optimization
    DOI:  https://doi.org/10.3390/healthcare14081019
  8. AAPS J. 2026 05 06. pii: 97. [Epub ahead of print]28(3):
      Continuous glucose monitoring (CGM) is widely used in type 1 diabetes management. Although less common in type 2 diabetes (T2D), its application is increasing, especially among patients with T2D on insulin therapy. CGM provides detailed, continuous glucose data that reveal daily glycemic fluctuations and help mitigate hyper- and hypoglycemic episodes. However, missing information on meal size and timing complicates the interpretation of data. To address these challenges, we propose a pharmacometric modeling approach that describes blood glucose profiles in patients with T2D receiving basal insulin in the absence of exact meal inputs. In this study, 73 individuals with T2D receiving insulin glargine plus oral antidiabetic medications (OAMs) underwent CGM assessments at four visits (Visit 3 on OAMs alone; Visits 13, 16, 20 on OAMs + insulin). Building upon the existing Integrated Glucose-Insulin (IGI) model, we incorporated a population meal model and an insulin glargine pharmacokinetic model, creating a comprehensive "meal-IGI-insulin" framework. The model identified three daily meal intakes, modeled as the sum of a surge function and a maximum bioavailable glucose amount of 7.83 g/hour. The model evaluation indicated adequate performance in predicting fasting blood glucose and HbA1c, though some discrepancies arose in forecasting hypoglycemic events. The developed modeling framework can facilitate prospective simulations of diverse meal patterns and insulin regimens, potentially accelerating antidiabetic drug development, simplify closed-loop automated insulin delivery algorithms, and optimize clinical strategies for patients with T2D.
    Keywords:  continuous glucose monitoring; insulin glargine; type 2 diabetes
    DOI:  https://doi.org/10.1208/s12248-026-01245-8
  9. Diabetol Int. 2026 Jul;17(3): 46
      Continuous glucose monitoring (CGM) has markedly advanced diabetes care by enabling real-time visualization of glycaemic variability, prevention of hypoglycaemia, and direct integration into therapeutic decision-making. As CGM use expands in routine practice and automated insulin delivery systems, however, accuracy has become a critical determinant of treatment safety. This mini-review summarizes recent advances in CGM accuracy management across three major driving forces: (1) accelerating technological innovation, including multi-analyte sensors, non-invasive devices, and artificial intelligence (AI)-based signal processing; (2) systematization and international harmonization of regulatory accuracy frameworks, exemplified by U.S. Food and Drug Administration (FDA) integrated CGM (iCGM) and the proposed CGM in Europe (eCGM) concept; and (3) growing societal demands for transparency, including public disclosure of performance data and strengthened lot-to-lot evaluation. We outline the four key dimensions of CGM accuracy-analytical accuracy, clinical accuracy, trend accuracy, and precision. We then review the evolution of regional accuracy standards, focusing on highly influential frameworks in the United States and Europe. Key considerations in accuracy-study design are discussed, along with clinical risks associated with reduced accuracy optimization, and progress toward global standardization. Finally, we examine future directions in the era of next-generation technologies, such as multi-analyte and non-invasive sensors, AI-driven accuracy optimization, and progress toward international standardization. This review provides an overview of the current landscape and future directions of CGM accuracy management in an era where fluctuations in accuracy directly affect treatment safety. We aim to clarify the perspectives required in both clinical practice and research to ensure safe and effective use of CGM.
    Keywords:  Accuracy; Continuous glucose monitoring; Error-grid analysis; Reliability
    DOI:  https://doi.org/10.1007/s13340-026-00901-w
  10. J Diabetes Res. 2026 ;2026(1): e3621409
      Continuous glucose monitors (CGMs) are essential tools for diabetes management; however, many state Medicaid programs do not have standardized, inclusive policies that ensure equitable access to CGMs for blind/low vision (BLV) and deaf/hard of hearing (DHH) populations, driving disparities across the United States and its territories. This policy analysis examines the barriers and facilitators to Medicaid CGM coverage for BLV and DHH populations, specifically in Medicaid and non-Medicaid expansion states, and patient choice in CGM device selection. CGM barrier language existed in 9.6% of states and U.S. territories, preventing BLV and DHH populations from accessing CGM. Facilitator language was present in 5.8% of states and U.S. territories, advocating for equitable access to CGMs for BLV individuals but not DHH individuals. Given the limitations of CGM alarms, this paper also emphasizes the need for Medicaid to cover secondary devices that provide needed haptic, visual, and audible alarms as necessary accessibility tools rather than optional add-ons. These devices are integral to ensuring a safe and independent CGM use for BLV and DHH individuals. Policy changes that prioritize health equity, framing CGM access as both a usability issue and a matter of eligibility for all Medicaid beneficiaries, is crucial.
    DOI:  https://doi.org/10.1155/jdr/3621409
  11. JMIR Diabetes. 2026 May 06. 11 e89374
       Background: Conventional clinical markers guide cardiovascular risk stratification; however, continuous glucose monitoring (CGM) data remain absent from prediction models. A synthesis of the current literature is needed to clarify the prognostic relevance of CGM data for cardiovascular outcomes in people with diabetes.
    Objective: This scoping review aimed to identify published studies examining (1) the associations between glycemic control and cardiovascular outcomes and (2) the predictive value of CGM-derived metrics in cardiovascular risk assessment.
    Methods: MEDLINE and Embase were searched from inception to March 11, 2025, for peer-reviewed, original research that included CGM-derived metrics and cardiovascular disease (CVD) outcomes. Two reviewers screened the records independently.
    Results: A total of 53 studies were identified. These studies focused on type 1 diabetes, type 2 diabetes, both diabetes types, or prediabetes. Clinical outcomes were examined in 16 studies, while subclinical outcomes were assessed in 40 studies. Of the 53 studies, 47 were cross-sectional studies and 6 were longitudinal studies. All studies were association studies, and 3 included secondary analyses of predictive performance. However, none applied machine learning-based methods. A wide range of CGM-derived metrics and CVD outcomes, both clinical and subclinical, were studied in the literature.
    Conclusions: Overall, the findings were inconsistent across studies, and this was likely due to methodological weaknesses such as underpowered analyses. Time-in-range was both the most studied metric and associated with cardiovascular risk in the largest single study. Only the mean amplitude of glycemic excursions was consistently associated with CVD in most studies investigating this metric, when using statistical significance as a pragmatic indicator of consistency across heterogeneous studies. The prognostic value of CGM-derived metrics for CVD outcomes is currently underexplored. Longitudinal prediction studies on clinical CVD outcomes, leveraging the potential of routinely collected CGM data, are needed.
    Keywords:  association; blood glucose; cardiovascular disease; cardiovascular risk; continuous glucose monitoring; diabetes; prediction; scoping review
    DOI:  https://doi.org/10.2196/89374
  12. Diabetes Ther. 2026 May 05.
       INTRODUCTION: Diabetes mellitus presents a growing public health challenge across geographies including Asia, particularly in countries where blood glucose monitoring (BGM)-referring to capillary finger-prick self-monitoring of blood glucose (SMBG) using a meter and test strips-is underutilized. Having evolved and improved over recent decades, glucose monitoring (GM)-including SMBG and continuous glucose monitoring (CGM)-has become an essential tool for effective diabetes management, yet remains underutilized because of systemic, economic, and educational barriers. This work synthesizes expert insights and published evidence to develop best practice recommendations for BGM.
    METHODS: A targeted literature review (TLR) was conducted across five thematic domains: monitoring practices, clinical decision-making, patient engagement and adherence, technology and innovation, and policy and reimbursement. Insights were complemented by a structured expert forum involving clinicians from seven Asian countries, underscoring larger implications in geographies where SMBG remains underutilized within the diabetes care continuum. The forum highlighted disparities in device access, affordability, and insurance coverage, and emphasized the need for structured diabetes self-management education (DSME) and digital integration.
    RESULTS: Findings support the use of structured SMBG for non-insulin-treated type 2 diabetes and CGM for insulin-treated individuals and those at risk of hypoglycemia. Evidence from the literature review also highlighted the importance of proper SMBG technique, with common errors such as inadequate handwashing, repeated lancet use, and excessive finger squeezing contributing to inaccurate readings and finger-site injuries. Hybrid models combining CGM and SMBG for calibration or confirmation are pragmatic solutions balancing clinical utility and affordability. Digital platforms, AI-driven analytics, and mobile apps enhance patient engagement and glycemic control but face challenges of scalability and regulation.
    CONCLUSION: Policy reforms, including inclusion of BGM in national health benefit packages, expanded insurance coverage, and public-private partnerships, are critical to improving access. The recommendations advocate for personalized, context-specific monitoring strategies that balance clinical efficacy with affordability and infrastructure realities. This consensus-based framework aims to guide healthcare professionals in optimizing BGM practices and improving long-term outcomes for people living with diabetes. FITTER BiG is a new extension of the long-standing FITTER initiative, which has provided insulin injection technique recommendations for more than two decades. FITTER BiG complements this work by focusing specifically on best practice recommendations for blood glucose monitoring. FITTER BiG will provide BGM-specific recommendations designed to complement the injection technique guidance outlined in the FITTER Forward consensus statement (Klonoff et al. Mayo Clin Proc 100:682-699, 2025 [1]).
    Keywords:  Asia; CGM; DSME; Diabetes education; Diabetes monitoring; Expert consensus; Health policy reform; SMBG
    DOI:  https://doi.org/10.1007/s13300-026-01867-3
  13. J Med Internet Res. 2026 May 08. 28 e86815
       Background: Diabetes technologies-including continuous glucose monitoring (CGM), insulin pumps, and hybrid closed-loop systems-have profoundly transformed self-management in type 1 diabetes (T1D). While these technologies offer improved glycemic control and safety, their use in ultraendurance sports introduces specific cognitive, material, and organizational challenges that remain underexplored in digital health research.
    Objective: This study aimed to explore how adults living with T1D experience and use diabetes technologies in ultraendurance sports, with particular attention to tensions between autonomy, mental load, and vulnerability.
    Methods: We conducted semistructured interviews with 13 French-speaking adults with T1D who had completed at least one marathon or ultra-endurance event within the last 5 years and used ≥1 diabetes technology (CGM, pump, or hybrid closed loop). We adopted constructivist grounded theory (Charmaz), using iterative cycles of line-by-line and focused coding, constant comparison, and memo-writing to build and refine analytic categories. Sampling combined purposive strategies through associations and online communities with theoretical orientation (additional participants sought to elaborate emergent categories). Data collection ceased upon theoretical sufficiency, when further interviews no longer yielded substantively new insights for core categories. Two patient partners contributed to question framing, interim sense-checking, and manuscript review. Reporting followed the COREQ (Consolidated Criteria for Reporting Qualitative Research) checklist.
    Results: Five interrelated categories described how athletes negotiated technology in practice: (1) From episodic control to continuous anticipation (reframing glucose management through real-time visibility); (2) Gains in safety and performance (perceived benefits and expanded possibilities); (3) Redistributed mental work (hyper-vigilance, logistics, device management); (4) Keeping things working when they break (fragility in extreme conditions, redundancy, improvisation, and experiential expertise); and (5) Making diabetes visible (technologies mediating identity, solidarity, and stigma). Across categories, participants articulated a tension between optimization-oriented performance and a user-constructed robustness-the capacity to maintain function under uncertainty through redundancy and adaptive know-how.
    Conclusions: In ultraendurance contexts, diabetes technologies act as both enablers and obligations: they open participation while shifting and sometimes intensifying cognitive and organizational work. A grounded account centered on robustness-in-use highlights practical implications for clinicians (pre-event routines, redundancy planning), designers (context-aware algorithms; improved physical durability), and policy makers (equitable access and exercise-specific education). These findings underscore the value of constructivist, practice-oriented inquiry to inform digital health tool design and support for people living with chronic illness.
    Keywords:  continuous glucose monitoring; diabetes mellitus, type 1; exercise; patient participation; qualitative research; self-management; type 1 diabetes
    DOI:  https://doi.org/10.2196/86815
  14. Metabolism. 2026 May 02. pii: S0026-0495(26)00136-8. [Epub ahead of print]181 156626
       BACKGROUND: Continuous glucose monitoring (CGM) reveals heterogeneity of postprandial glucose responses (PPGR), a key target for optimizing glycemic control in type 2 diabetes (T2D). We analyzed PPGR patterns to identify subtypes reflecting pathophysiological differences.
    METHODS: Cross-sectional CGM data from 100 individuals with T2D were collected over 4 h following a standardized meal consumed twice. Dynamic PPGR features-glucose peak, incremental area under the curve (iAUC), rise and fall rates, final vs. fasting glucose-were used for K-Means clustering, with stability assessed using a Random Forest classifier trained on the first meal. In 50 participants, postprandial plasma glucose and insulin were measured, and clinical/metabolic parameters compared across clusters using one-way ANOVA.
    RESULTS: Three CGM-defined PPGR clusters were identified. Cluster 1 (n = 19) showed the highest peak and iAUC, with post-meal glucose remaining persistently above baseline. Cluster 2 (n = 56) and 3 (n = 25) had lower peaks and iAUCs, but Cluster 3 exhibited higher rise and fall rates than Cluster 2. Clusters did not differ in age, sex, BMI, or diabetes duration, but metformin use was lower in Cluster 3. Cluster 1 showed significantly lower insulin secretion (HOMA2-B%: 77.42 ± 25.64 vs. 104.96 ± 43.94) and higher insulin resistance (HOMA-IR: 7.94 ± 3.27 vs. 4.84 ± 2.78) than Cluster 3, with intermediate values for Cluster 2, confirmed by postprandial indices. Cluster 3 had a higher early insulin response than Cluster 1 and 2 (60-min insulinogenic index: 1.67 ± 1.07, 0.84 ± 0.31, 0.84 ± 0.58, respectively; p < 0.05).
    CONCLUSIONS: CGM-derived PPGR features could identify T2D subtypes with similar clinical profiles but distinct insulin secretion and sensitivity impairments, supporting targeted interventions.
    Keywords:  Beta-cell function; Clusters; Continuous glucose monitoring; Heterogeneity; Insulin resistance; Postprandial glucose response
    DOI:  https://doi.org/10.1016/j.metabol.2026.156626
  15. Diabetes Obes Metab. 2026 May 05.
       BACKGROUND: Advanced diabetes technologies are standard of care for people with Type 1 diabetes (T1D). However, inequitable access contributes to disparities in outcomes.
    PURPOSE: To characterise barriers and enablers to the use of advanced diabetes technologies among individuals with T1D and to synthesise these determinants using the Theoretical Domains Framework.
    DATA SOURCES: EMBASE, Cochrane, PubMed, and MEDLINE were systematically searched from January 1, 2000, to September 30, 2025.
    STUDY SELECTION: We included studies of any design examining characteristics associated with the use of insulin pumps, continuous glucose monitors (CGM), or automated insulin delivery (AID) in T1D.
    DATA EXTRACTION: Two reviewers independently screened and extracted data using a standardised tool. Determinants were categorised as non-modifiable or potentially modifiable barriers or enablers. Modifiable determinants were mapped to TDF domains to enable theory-informed synthesis.
    DATA SYNTHESIS: Of 3081 citations identified, 303 studies (1 864 469 participants) were included. Non-modifiable determinants most frequently associated with technology use included racial/ethnic minority status (n = 90), age (n = 53), sex (n = 36), and socioeconomic status (n = 40). Potentially modifiable determinants clustered primarily within six TDF domains, most commonly Environmental Context and Resources, Social Influences, Knowledge, Skills, Beliefs about Consequences, and Emotions. Within these domains, key barriers included financial constraints (n = 117), provider gatekeeping and clinic processes (n = 43), and physical burden or body image concerns (n = 41). Key enablers included supportive patient-provider relationships and shared decision-making (n = 42), patient education and knowledge of device benefits (n = 40), and proactive provider engagement (n = 24).
    LIMITATIONS: A large proportion of abstracts (35.3% overall; 70.6% of interventions), potential publication bias, exclusion of grey literature, predominance of US-based studies (62.4%), and few AID-only studies (6.9%) may limit generalisability.
    CONCLUSIONS: Barriers to diabetes technology use map to key TDF domains, with structural factors predominating. Multilevel interventions targeting health system processes, provider practices, and education are needed to improve equitable uptake.
    Keywords:  barriers; continuous glucose monitoring (CGM); insulin pump therapy; type 1 diabetes
    DOI:  https://doi.org/10.1111/dom.70819